Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2015
At a glance
- Drugs PE 0139 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors PhaseBio Pharmaceuticals
- 09 Jun 2015 Interim results (n=8) presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 08 Jun 2015 Results of this study were published in a PhaseBio Pharmaceuticals media release.
- 08 Jun 2015 According to a PhaseBio Pharmaceuticals media release, positive data of this study was presented at the American Diabetes Association 75th Scientific Sessions 2015.